{"groups":[{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"FG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.","id":"FG001","title":"Ado-trastuzumab Emtansine (T-DM1)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"66"},{"groupId":"FG001","numSubjects":"158"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"12"}],"type":"Clinical Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"17"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"11"}],"type":"Withdrawal by Subject (from treatment only)"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}],"type":"Miscellaneous"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"261"},{"groupId":"FG001","numSubjects":"263"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"136"},{"groupId":"FG001","numSubjects":"49"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"125"},{"groupId":"FG001","numSubjects":"214"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 524 participants were enrolled and treated at study sites in 14 countries. Primary results reported is from first participant randomized up to data cut-off date of 21 May 2021. The results presented are based on primary analysis up to 33 months. Data collection is still on-going and additional results will be provided after study completion."}